Editorial Team of Labiotech.eu

In Depth 27 Jul 2022

The race to uncloak cancer with liquid biopsies

Until recently, cancer detection depended on invasive solid tissue sampling that didn’t provide a complete picture. An emerging crowd of biotechs is making it easier to detect and monitor cancer with liquid biopsies. The notion that a person’s blood can reveal a wealth of health information looked so shiny that the infamous blood diagnostics company […]

July 27, 2022 - 10 minutesmins - By Editorial Team

News and Trends 30 Mar 2022

BIO-Europe Spring 2022: The Highlights

BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings, published as they happen. BIO-Europe Spring 2022 is in full swing this week with a long lineup of online topic discussions. Labiotech.eu […]

March 30, 2022 - 13 minutesmins - By Editorial Team

News and Trends 30 Sep 2019

Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close

Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […]

September 30, 2019 - 4 minutesmins - By Editorial Team

Inside Labiotech 6 Dec 2018

We Are Now More Than 150,000 Awesome Biotechers Every Month

Woohooo! We’ve hit 150,000 unique visitors per month to our site! What a beautiful number. We are so happy to be able to bring you great content every day and have our biotech network grow with more amazing people. Why this makes us so happy? Because it means that, 150,000 different people stopped by our website […]

December 6, 2018 - 2 minutesmins - By Editorial Team

Genome Sequence Human Genome Update Feature Header

In Depth 4 Sep 2018

The Past, Present and Future of Genome Sequencing

The last two decades have seen a revolution in genome sequencing with dramatic increases in speed and efficiency coupled with massive reductions in cost. There is so much going on in this area it can be difficult to keep up, so here is what you should know. Gene sequencing has proved its usefulness as a […]

September 4, 2018 - 9 minutesmins - By Editorial Team

News and Trends 4 Sep 2018

The EMA Approves the First Nanobody from Ablynx

Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in June. The drug has also been accepted for priority review by the US FDA, with a decision due on 6 Feb 2019. Published 29.6.18 Just a few months after Sanofi acquired Ablynx in a multi-billion euro […]

September 4, 2018 - 2 minutesmins - By Editorial Team

In Depth 29 Aug 2018

How Big is the Investment Gap Between Biotech and Digital? (Smaller Than You Think…)

Many people outside of biotech may wonder how the size of the biotech industry compares to the digital industry, and even biotech experts often don’t know the answer. Here we’ll take a look at how the two industries compare and how they are expected to develop in the future. We cannot get around the fact […]

August 29, 2018 - 7 minutesmins - By Editorial Team

News and Trends 28 Aug 2018

Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe

Update: Following on from earlier approvals in the US, the European Commission announced it has given marketing approval for both Gilead’s Yescarta and Novartis’s Kymriah for treatment of patients with various forms of blood cancer. Yescarta (axicabtagene ciloleucel) can be used to treat adults with a relapsed or refractory form of the blood cancer diffuse large […]

August 28, 2018 - 4 minutesmins - By Editorial Team

Interview 24 Jul 2018

Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug”

Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […]

July 24, 2018 - 6 minutesmins - By Editorial Team

News and Trends 29 Jun 2018

Update: Yet Another ADC Company Makes Bank, This Time in Series B

Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M), reaching a total of 40M CHF (€34.6M) for the round. Novo Holdings joins the Boehringer Ingelheim Venture Fund and the PPF Capital Partners Fund as a major shareholder of the Swiss biotech, which continues to develop its ADCs for improved […]

June 29, 2018 - 3 minutesmins - By Editorial Team

Interview 25 Apr 2018

Planting the Seeds to Grow the Italian Biotech Industry

Many European countries, including the UK, France, Germany, and Switzerland, boast a thriving biotech industry. Others are still a step behind when it comes to industrializing their research. Let’s take a look at how Italy is pushing through to make it to the first league. Italy is certainly a pioneer and leader in life science research — […]

April 25, 2018 - 3 minutesmins - By Editorial Team

News and Trends 23 Apr 2018

The First CAR-T Therapy Is Not Living Up to Commercial Expectations

Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […]

April 23, 2018 - 3 minutesmins - By Editorial Team

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us